SCM
ORIC icon

Silverarc Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Silverarc Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Sell
1,100,010
-16,594
-1% -$188K 1.42% 21
2025
Q4 		$9.13M Sell
1,116,604
-832,204
-43% -$9.58M 1.27% 27
2025
Q3 		$23.4M Buy
1,948,808
+147,979
+8% +$1.56M 3.15% 12
2025
Q2 		$18.3M Sell
1,800,829
-259,411
-13% -$1.74M 3.37% 11
2025
Q1 		$11.5M Buy
2,060,240
+881,940
+75% +$7.71M 2.35% 15
2024
Q4 		$9.51M Buy
1,178,300
+78,810
+7% +$723K 2.08% 17
2024
Q3 		$11.3M Buy
1,099,490
+23,678
+2% +$234K 2.53% 13
2024
Q2 		$7.61M Sell
1,075,812
-37,195
-3% -$333K 1.79% 17
2024
Q1 		$15.3M Sell
1,113,007
-56,993
-5% -$677K 4.25% 4
2023
Q4 		$10.8M Buy
1,170,000
+46,655
+4% +$337K 3.2% 10
2023
Q3 		$6.8M Sell
1,123,345
-327,477
-23% -$2.68M 2.06% 16
2023
Q2 		$11.3M Buy
1,450,822
+14,877
+1% +$84.5K 3.48% 8
2023
Q1 		$8.18M Buy
1,435,945
+199,649
+16% +$1.04M 3.38% 5
2022
Q4 		$7.28M Buy
1,236,296
+27,304
+2% +$92.2K 2.08% 17
2022
Q3 		$3.87M Buy
1,208,992
+126,688
+12% +$507K 1.31% 29
2022
Q2 		$4.85M Buy
+1,082,304
New +$4.32M 1.49% 22

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Silverarc Capital Management's ORIC Position: Q1 2026 in Review

Silverarc Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 1.5% in Q1 2026, selling an estimated $188K and leaving 1,100,010 shares worth $13.9M. The position accounts for 1.42% of the portfolio, ranked #21.

Silverarc Capital Management first reported a position in ORIC in Q2 2022 and has held it in 16 quarters since. The position peaked at $23.4M in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Silverarc Capital Management held 1,100,010 shares of Oric Pharmaceuticals worth $13.9M as of Q1 2026.
  • Silverarc Capital Management sold 16,594 Oric Pharmaceuticals shares in Q1 2026, an estimated $188K.
  • Oric Pharmaceuticals made up 1.42% of Silverarc Capital Management's portfolio in Q1 2026, its #21 holding.
  • Silverarc Capital Management first reported a position in Oric Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Silverarc Capital Management's Oric Pharmaceuticals position peaked at $23.4M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.